Hanh

//Hanh

About Hanh

This author has not yet filled in any details.
So far Hanh has created 97 blog entries.

IVI’s Mark Linthicum in Morning Consult: Why Understanding Value is Central to True Health Care Reform

Mark Linthicum makes the case that value-based spending should be the focus of health care reform efforts in Washington, D.C. On September 13th health care stakeholders came together at the National Press Club to discuss better approaches to measuring value. Read Full Article Here

2017-11-11T01:18:31+00:00 September 20th, 2017|Viewpoints|

IVI-Sponsored Health Affairs Policymaker Forum Assembles Key Stakeholders

On September 13th, the Innovation and Value Initiative was proud to sponsor a special Health Affairs briefing in Washington, D.C. Over 200 of the country's most influential health care stakeholders and public policy thought leaders gathered to address the topic of value in health care. Focusing on "Understanding the Value of Innovations in Medicine," this [...]

2017-11-09T02:39:59+00:00 September 14th, 2017|Event|

Shafrin Defines Precision Medicine for U.S. News and World Report

In a new commentary for U.S. News and World Report, Jason Shafrin defines and elaborates on the field of precision medicine. Jason, IVI's Director of Research, illustrates how the United States is moving headlong into this new treatment approach. He notes some of the challenges while also emphasizing the unique hope precision medicine brings through [...]

2017-11-11T01:22:04+00:00 August 25th, 2017|Viewpoints|

Sachs Provides an Overview of FDA User Fee Reauthorization Bill

In a recent post on the IVI-Sponsored Health Affairs blog series, Rachel Sachs provides an overview of the House of Representative's latest draft of the FDA user fee authorization bill. Sachs also examines changes in the bill from the earlier Senate markup, including incorporation of provisions from the bipartisan RACE Act and provides a possible [...]

2017-11-09T02:27:26+00:00 July 13th, 2017|Viewpoints|

IVI Highlighted in Article on Value Assessment in Oncology Treatments

In this month's Drug Topics, correspondent Kathleen Gannon Longo speaks with Jeremy Schafer about the potentially tremendous impact that value assessments will have on future patient reimbursement decisions. Focusing on Oncology treatment, Schafer describes some of the existing value frameworks in play as well as referencing the work being done by the IVI to employ [...]

2017-09-06T14:10:04+00:00 June 28th, 2017|Press|

Sachs Summarizes Recent HELP Committee Meeting: The Elephant in the Room

In the latest post on the the IVI-sponsored Health Affairs blog series, Rachel Sachs summarizes the recent Senate Health, Education, Labor & Pensions (HELP) Committee meeting. Organized to address the drug delivery system and how it influences what patients pay, the meeting quickly shifted to a partisan blasting of the secretive process by which Republicans [...]

2017-07-14T05:22:13+00:00 June 20th, 2017|Viewpoints|

Lietzan Examines SCOTUS Ruling on Biosimilars

In the latest post on the the IVI-sponsored Health Affairs blog series, Drugs and Medical Innovation, Erica Lietzan takes a look at the recent Supreme Court ruling on Sandoz v. Amgen, examining premarket patent litigation, patent resolution process, state law influence, and the impact of the SCOTUS ruling itself. Read the full article here.

2017-07-14T05:22:20+00:00 June 19th, 2017|Viewpoints|

IVI’s Lakdawalla in WSJ: Look to Major League Baseball for Drug Pricing Insight

In a new commentary appearing in The Wall Street Journal, Dana Goldman and IVI Executive Director, Darius Lakdawalla, turn to the national pastime to provide a fresh perspective on the issue of drug pricing and the return on investment pharmaceutical companies need to sustain innovation. In baseball, the salaries are high and the talent pool is [...]

2017-07-18T22:26:51+00:00 June 19th, 2017|Viewpoints|

Discussing the Challenges of Value-Based Pricing in STAT News

In a new commentary for STAT News, Anupam Jena (part of IVI's scientific advisory group) and Dana Goldman discuss the advantages of value-based pricing, pointing out several of the key challenges that complicate the application of health technology assessments. Jena and Goldman make the case that more transparency is needed and that an open-source model [...]

2017-07-18T22:27:01+00:00 June 14th, 2017|Viewpoints|

IVI Releases Protocol for Report on Cost-Effectiveness Analysis in Health Care

IVI released the research protocol for its first project, which examines the quality of evidence and methods used in cost-effectiveness analysis (CEA) in healthcare. The research protocol is available here. This is the first research project in a series that will look at issues of relevance to policy, value assessment practices or methods, economic questions related [...]

2017-07-18T22:27:06+00:00 June 14th, 2017|Research|